PHIO Valuation
Phio Pharmaceuticals Corp
$
2.180
- Overview
- Forecast
- Valuation
- Earnings
PHIO Relative Valuation
PHIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PHIO is overvalued; if below, it's undervalued.
Historical Valuation
Phio Pharmaceuticals Corp (PHIO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -2.30. The fair price of Phio Pharmaceuticals Corp (PHIO) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 2.18 USD , Phio Pharmaceuticals Corp is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：2.18
Fair
Undervalued
-1.57
PE
1Y
3Y
5Y
Trailing
Forward
0.03
EV/EBITDA
Phio Pharmaceuticals Corp. (PHIO) has a current EV/EBITDA of 0.03. The 5-year average EV/EBITDA is 0.01. The thresholds are as follows: Strongly Undervalued below -0.09, Undervalued between -0.09 and -0.04, Fairly Valued between 0.06 and -0.04, Overvalued between 0.06 and 0.11, and Strongly Overvalued above 0.11. The current Forward EV/EBITDA of 0.03 falls within the Historic Trend Line -Fairly Valued range.
0.03
EV/EBIT
Phio Pharmaceuticals Corp. (PHIO) has a current EV/EBIT of 0.03. The 5-year average EV/EBIT is -0.21. The thresholds are as follows: Strongly Undervalued below -3.51, Undervalued between -3.51 and -1.86, Fairly Valued between 1.44 and -1.86, Overvalued between 1.44 and 3.09, and Strongly Overvalued above 3.09. The current Forward EV/EBIT of 0.03 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Phio Pharmaceuticals Corp. (PHIO) has a current PS of 0.00. The 5-year average PS is 0.30. The thresholds are as follows: Strongly Undervalued below -0.86, Undervalued between -0.86 and -0.28, Fairly Valued between 0.88 and -0.28, Overvalued between 0.88 and 1.46, and Strongly Overvalued above 1.46. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Phio Pharmaceuticals Corp. (PHIO) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Phio Pharmaceuticals Corp. (PHIO) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.18. The thresholds are as follows: Strongly Undervalued below -0.53, Undervalued between -0.53 and -0.17, Fairly Valued between 0.54 and -0.17, Overvalued between 0.54 and 0.89, and Strongly Overvalued above 0.89. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Phio Pharmaceuticals Corp (PHIO) has a current Price-to-Book (P/B) ratio of 0.86. Compared to its 3-year average P/B ratio of 0.53 , the current P/B ratio is approximately 62.13% higher. Relative to its 5-year average P/B ratio of 0.66, the current P/B ratio is about 30.57% higher. Phio Pharmaceuticals Corp (PHIO) has a Forward Free Cash Flow (FCF) yield of approximately -60.71%. Compared to its 3-year average FCF yield of -270.81%, the current FCF yield is approximately -77.58% lower. Relative to its 5-year average FCF yield of -187.85% , the current FCF yield is about -67.68% lower.
0.86
P/B
Median3y
0.53
Median5y
0.66
-60.71
FCF Yield
Median3y
-270.81
Median5y
-187.85
Competitors Valuation Multiple
The average P/S ratio for PHIO's competitors is 1.51, providing a benchmark for relative valuation. Phio Pharmaceuticals Corp Corp (PHIO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PHIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PHIO in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Phio Pharmaceuticals Corp (PHIO) currently overvalued or undervalued?
Phio Pharmaceuticals Corp (PHIO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -2.30. The fair price of Phio Pharmaceuticals Corp (PHIO) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 2.18 USD , Phio Pharmaceuticals Corp is Undervalued By Fair .
What is Phio Pharmaceuticals Corp (PHIO) fair value?
How does PHIO's valuation metrics compare to the industry average?
What is the current P/B ratio for Phio Pharmaceuticals Corp (PHIO) as of Aug 18 2025?
What is the current FCF Yield for Phio Pharmaceuticals Corp (PHIO) as of Aug 18 2025?
What is the current Forward P/E ratio for Phio Pharmaceuticals Corp (PHIO) as of Aug 18 2025?